Moberg Pharma´s Interim report January - September 2023
Moberg Pharma´s Interim report January - September 2023MOB-015 HAS RECEIVED NATIONAL APPROVALS IN 10 EU COUNTRIES, ANOTHER 3 APPROVALS ARE EXPECTEDNINE-MONTH PERIOD (JAN-SEP 2023)· EBITDA SEK -17.4 million (-13.7)· Operating profit (EBIT...
Source: pharmiweb.com